Cabotegravir Sodium Patent Expiration
Cabotegravir Sodium is Used for treating HIV-1 infection in adults and adolescents over 12 years old with a weight of at least 35 kg. It was first introduced by Viiv Healthcare Co
Cabotegravir Sodium Patents
Given below is the list of patents protecting Cabotegravir Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vocabria | US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity | Apr 28, 2026 | Viiv Hlthcare |
| Vocabria | US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | Apr 28, 2026 | Viiv Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳